New article: Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells

Stefan Krauss participated in a study by the laboratory of Jens Preben Morth (University of Copenhagen, Demark) Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells”.

Image may contain: Text, Organism.Stefan Krauss participated in a study by the laboratory of Jens Preben Morth (University of Copenhagen, Demark) Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells”. Sjögren syndrome/scleroderma autoantigen 1 (SSSCA1) was first described as an auto-antigen over-expressed in Sjögren’s syndrome and in scleroderma patients. This study characterizes SSSCA1 for the first time at the molecular, structural and subcellular level. It presents the crystal structure of a zinc finger fold, a zinc ribbon domain type 2 (ZNRD2), at 2.3 Å resolution. Furthermore, the study shows that the C-terminal domain serves a dual function as it both behaves as the interaction site to Tankyrase 1 (TNKS1) and as a nuclear export signal. TNKS1 is identified as a direct binding partner of SSSCA1. By mapping the SSSCA1 binding site to the TNKS1 ankyrin repeat cluster 2 (ARC2) a new binding sequence is defined.

The study was published in Communications Biology (Nature group, impact factor 7.5 - 10)

Read it here: https://www.nature.com/articles/s42003-020-0851-2

 

Published May 12, 2020 9:30 AM - Last modified May 12, 2020 9:30 AM